| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CLEC1B |
| Uniprot No | Q9P126 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-196aa |
| 氨基酸序列 | MQDEDGYITLNIKTRKPALVSAVMQRNYLQDENENRTGTLQQLAKRFCQYVVKQSELKGTFKGHKCSPCDTNWRYYGDSCYGFFRHNLTWEESKQYCTDMNATLLKIDNRNIVEYIKARTHLIRWVGLSRQKSNEVWKWEDGSVISENMFEFLEDGKGNMNCAYFHNGKMHPTFCENKHYLMCERKAGMTKVDQLP |
| 分子量 | 49.5 KDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人CLEC1B蛋白的3篇代表性文献(信息基于公开研究总结，具体内容建议通过学术数据库核实)：
---
1. **文献名称**: *Podoplanin binds to CLEC-2 on platelets to trigger platelet activation in tumors*
**作者**: Suzuki-Inoue, K., et al.
**摘要**: 研究通过重组人CLEC1B(CLEC-2)蛋白，证实其与肿瘤细胞表面的podoplanin特异性结合，激活血小板并促进肿瘤转移。实验表明CLEC1B在肿瘤微环境中的信号通路调控中起关键作用。
---
2. **文献名称**: *Structural basis of CLEC-2 recognition by rhodocytin sheds light on platelet activation*
**作者**: Watson, A.A., et al.
**摘要**: 利用重组CLEC1B蛋白解析其晶体结构，揭示其与蛇毒蛋白rhodocytin的相互作用机制，阐明了CLEC1B胞外结构域的C型凝集素特征及其介导血小板活化的分子基础。
---
3. **文献名称**: *CLEC1B variants and risk of thromboembolic disease: Functional studies using recombinant proteins*
**作者**: Christou, C.M., et al.
**摘要**: 通过表达重组CLEC1B蛋白，分析其基因多态性对配体结合能力的影响，发现特定突变会降低与podoplanin的亲和力，可能关联血栓性疾病风险。
---
如需更完整的文献列表，建议在PubMed或Web of Science中检索“recombinant human CLEC1B”或“CLEC-2 recombinant protein”。
Recombinant human CLEC1B (C-type lectin domain family 1 member B), also known as CLEC-2. is a transmembrane glycoprotein belonging to the C-type lectin-like receptor family. It is primarily expressed on platelets, megakaryocytes, and myeloid cells. CLEC1B plays critical roles in hemostasis, thrombosis, and immune regulation by interacting with specific ligands. Its best-characterized ligand is podoplanin, a transmembrane glycoprotein expressed by lymphatic endothelial cells, certain immune cells, and tumor cells. This CLEC1B-podoplanin interaction facilitates platelet activation, tumor metastasis, and lymphangiogenesis.
Structurally, CLEC1B contains an extracellular C-type lectin-like domain, a transmembrane domain, and a short cytoplasmic tail lacking intrinsic signaling motifs. Instead, it relies on associated proteins like the adaptor molecule CLEC-2-associated protein (CLEC-2-AP) for signal transduction. Recombinant CLEC1B is produced using mammalian expression systems to preserve post-translational modifications and ligand-binding activity. It serves as a vital tool for studying platelet biology, cancer progression, and inflammatory diseases.
Research using recombinant CLEC1B has elucidated its involvement in pathological conditions, including arterial thrombosis, tumor cell extravasation, and infectious disease responses. It also holds therapeutic potential as a target for antithrombotic drugs or inhibitors of cancer metastasis. Ongoing studies explore its interactions with viral pathogens, suggesting broader roles in immunity.
×
